Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from PainReform ( (PRFX) ).
On March 27, 2026, PRF Technologies issued a year-end 2025 update detailing a strategic pivot into dual platforms in healthcare and renewable-energy analytics. The company reported a sharply reduced annual net loss of about $4.8 million versus $14.6 million in 2024, supported by lower R&D spending, $4.1 million in year-end liquidity, positive working capital and $4.0 million in 2025 at-the-market equity proceeds.
In healthcare, PRF highlighted its August 2025 majority investment in Boston-based LayerBio and the addition of OcuRing-K, a patented bio-erodible intraocular ring designed to deliver ketorolac during cataract surgery. The company advanced OcuRing-K through IND-supporting work for a planned Phase II trial, building on preclinical and Phase I safety data, and reported R&D findings that LayerBio’s sustained-release platform can carry multiple agents, expanding its potential beyond a single post-cataract pain and inflammation product.
In renewable energy, PRF said its March 2025 acquisition of DeepSolar has evolved from a technology buy into an early-stage commercial AI solar analytics business. DeepSolar moved from a pilot with Econergy at a 92 MW Romanian plant to a commercial agreement and, in February 2026, secured a SaaS contract with Shikun & Binui Energy for a 71 MW site, while also entering its first announced due diligence engagement with EDF Power Solutions Israel.
During late 2025 and early 2026, DeepSolar launched its Smart TDD due-diligence service, completed a Smart Energy Management app, advanced an automated reporting engine and joined NVIDIA’s Connect Program to support its DeepSolar Predict offering. PRF also filed a first patent application covering micro-climate forecast modeling for solar plants, underscoring management’s view that the unit is well-positioned amid rising utility-scale solar deployment and demand for analytics-driven performance optimization.
The most recent analyst rating on (PRFX) stock is a Sell with a $0.64 price target. To see the full list of analyst forecasts on PainReform stock, see the PRFX Stock Forecast page.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Neutral.
The score is weighed down primarily by weak financial performance (minimal revenue, widening losses, and rising cash burn alongside shrinking equity). Technicals also remain bearish with the stock trading below key moving averages, while valuation cannot be meaningfully assessed due to missing P/E and dividend yield data.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PRF Technologies Ltd. (Nasdaq: PRFX) is a diversified innovation company operating in healthcare and AI-driven solar analytics, with principal offices in Tel Aviv, Israel. Its healthcare portfolio centers on sustained-release ocular drug-delivery technologies via its majority-owned LayerBio unit, while its DeepSolar platform targets utility-scale solar asset monitoring, forecasting and technical due diligence for global renewable-energy operators and investors.
Average Trading Volume: 531,803
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.85M
For a thorough assessment of PRFX stock, go to TipRanks’ Stock Analysis page.